ArticleNeurology(R) neuroimmunology & neuroinflammation2015
Preclinical development and first-in-human study of ATX-MS-1467 for immunotherapy of MS.
Article in Neurology(R) neuroimmunology & neuroinflammation, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 1 synthesis or guideline pooled it, 81 citations in OpenAlex.
- Safety and efficacy of antigen-specific therapeutic approaches for multiple sclerosis: Systematic review.PloS one · 2025Pooled it
- Trial
- Vaccines for Autoimmune Diseases: Stopping Triggers, Restoring BalanceA Systematic Review with Qualitative Synthesis.Mediterranean journal of rheumatology · 2026Review
- Targeting the pMHC-TCR Interaction: Molecular Strategies and Therapeutic Potential in Autoimmunity.International journal of molecular sciences · 2026Review
- Antigen-Specific Inverse Vaccination Strategies Using Particle Systems for Multiple Sclerosis.ACS biomaterials science & engineering · 2026Review
- How to manage autoimmune hyperthyroidism (Graves' disease): from differential diagnosis to emerging immunological therapies.Drugs in context · 2026Review
- Multiple sclerosis: molecular pathogenesis and therapeutic intervention.Signal transduction and targeted therapy · 2025Review
- A dominant, pan-DR binding epitope of Der p 1 in house dust mite allergy induces tolerance in HLA-DR4 transgenic mice.Frontiers in immunology · 2025Article
- 'Immune reset plus': the case for combining immunotherapies to maintain self-tolerance in autoimmune diseases.Frontiers in immunology · 2025Article
- Evolving understanding of autoimmune mechanisms and new therapeutic strategies of autoimmune disorders.Signal transduction and targeted therapy · 2024Review
- The brain cytokine orchestra in multiple sclerosis: from neuroinflammation to synaptopathology.Molecular brain · 2024Review
- Strategies and delivery systems for cell-based therapy in autoimmunity.Frontiers in drug delivery · 2024Review
- Neuroprotective Potential of Dendritic Cells and Sirtuins in Multiple Sclerosis.International journal of molecular sciences · 2022Review
- Antigen-specific immunotherapy with apitopes suppresses generation of FVIII inhibitor antibodies in HLA-transgenic mice.Blood advances · 2022Article
- Preclinical models of arthritis for studying immunotherapy and immune tolerance.Annals of the rheumatic diseases · 2021Review
- An Overview of Peptide-Based Molecules as Potential Drug Candidates for Multiple Sclerosis.Molecules (Basel, Switzerland) · 2021Review
- Made to Measure: Patient-Tailored Treatment of Multiple Sclerosis Using Cell-Based Therapies.International journal of molecular sciences · 2021Review
- Manipulating antigen presentation for antigen-specific immunotherapy of autoimmune diseases.Current opinion in immunology · 2021Review
- Antigen-Specific Immune Tolerance in Multiple Sclerosis-Promising Approaches and How to Bring Them to Patients.Frontiers in immunology · 2021Review
- Advancement of antigen-specific immunotherapy: knowledge transfer between allergy and autoimmunity.Immunotherapy advances · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
objectiveThe study was designed to test the efficacy of ATX-MS-1467 in a relevant preclinical model and to assess its safety for the treatment of patients with secondary progressive multiple sclerosis (SPMS).
methodsATX-MS-1467 was tested for its ability to suppress experimental autoimmune encephalomyelitis (EAE) in the (Ob x DR2)F1 mouse both before and after disease onset. Safety was assessed by clinical assessment, MRI analysis, and the measurement of immune responses to self- and nonself-antigens in patients with SPMS.
resultsATX-MS-1467 displayed a dose-dependent inhibition of EAE and was more effective than glatiramer acetate in the treatment of ongoing disease in humanized mice. A phase 1 open-label dose-escalating study demonstrated that ATX-MS-1467 was safe and well-tolerated in a group of 6 patients with SPMS, up to a dose of 800 µg.
conclusionsThe results of this study support further development of ATX-MS-1467 in a clinical trial powered to investigate the immunologic and clinical benefits of treatment in relapsing-remitting MS. CLASSIFICATION OF EVIDENCE: This study provides Class IV evidence that ATX-MS-1467 is safe and tolerated in a group of 6 patients with SPMS.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.